NCT00321893View on ClinicalTrials.gov

Budesonide in Treating Patients With Lung Nodules at High Risk of Developing Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

225

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Lung Cancer
Interventions
DRUG

Budesonide

Inhaled Budesonide 800 micrograms (ug) twice daily for one year.

OTHER

Placebo

Inhaled placebo twice daily for one year.

Trial Locations (1)

20141

European Institute of Oncology, Milan

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00321893 - Budesonide in Treating Patients With Lung Nodules at High Risk of Developing Lung Cancer | Biotech Hunter | Biotech Hunter